Q1 EPS Estimate for Zevra Therapeutics Raised by Analyst

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities researchers at Roth Capital raised their Q1 2025 earnings estimates for Zevra Therapeutics in a report issued on Tuesday, March 11th. Roth Capital analyst J. Aschoff now forecasts that the company will earn ($0.17) per share for the quarter, up from their previous estimate of ($0.27). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q2 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at ($0.10) EPS, FY2026 earnings at $0.81 EPS, FY2027 earnings at $1.38 EPS and FY2028 earnings at $1.79 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The company had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%.

A number of other brokerages also recently weighed in on ZVRA. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a report on Wednesday. Guggenheim increased their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday. Canaccord Genuity Group increased their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Thursday. Finally, Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $22.14.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA opened at $8.31 on Friday. The company has a market capitalization of $449.70 million, a price-to-earnings ratio of -4.22 and a beta of 1.98. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76. The stock has a fifty day simple moving average of $7.93 and a 200 day simple moving average of $8.16. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares in the company, valued at approximately $403,697.46. The trade was a 17.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Neil F. Mcfarlane sold 61,273 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the transaction, the chief executive officer now owns 222,060 shares of the company’s stock, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ZVRA. Adage Capital Partners GP L.L.C. boosted its stake in shares of Zevra Therapeutics by 462.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock worth $30,441,000 after buying an additional 3,001,000 shares during the last quarter. FMR LLC boosted its stake in shares of Zevra Therapeutics by 282,687.5% in the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after buying an additional 2,312,384 shares during the last quarter. AIGH Capital Management LLC purchased a new position in shares of Zevra Therapeutics in the 4th quarter worth approximately $6,577,000. Stonepine Capital Management LLC purchased a new position in shares of Zevra Therapeutics in the 3rd quarter worth approximately $4,858,000. Finally, Vestal Point Capital LP purchased a new position in shares of Zevra Therapeutics in the 3rd quarter worth approximately $3,644,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.